Galera Therapeutics Faces Delisting Notice
Ticker: GRTX · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1563577
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Galera Therapeutics got a notice about possibly getting delisted. Big trouble.
AI Summary
Galera Therapeutics, Inc. filed an 8-K on March 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 45 Liberty Blvd, Suite 230, Malvern, PA 19355. The report was filed as of March 21, 2024.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and trading of Galera Therapeutics' stock.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and investor confidence.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- March 21, 2024 (date) — Earliest event reported
- March 27, 2024 (date) — Date of report
- 45 Liberty Blvd, Suite 230, Malvern, PA 19355 (location) — Principal executive offices
FAQ
What specific listing rule or standard has Galera Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Galera Therapeutics has failed to satisfy, only that a notice has been received.
What is the earliest date of the event reported in this 8-K?
The earliest date of the event reported is March 21, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed on March 27, 2024.
What is the primary business of Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Galera Therapeutics, Inc.'s principal executive offices located?
Galera Therapeutics, Inc.'s principal executive offices are located at 45 Liberty Blvd, Suite 230, Malvern, PA 19355.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 13.4 · Accepted 2024-03-27 07:31:01
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX The Nasdaq
- $50,000,000 — Value of Listed Securities ("MVLS") of $50,000,000 required for continued listing on The N
- $1.00 — (the "Common Stock"), closes above the $1.00 per share minimum bid price requirement
- $15,000,000 — ue of Publicly Held Shares ("MVPHS") of $15,000,000 required for continued listing on The N
- $1,000,000 — market value of publicly held shares of $1,000,000 and all of the other initial listing cr
Filing Documents
- d797057d8k.htm (8-K) — 27KB
- 0001193125-24-078226.txt ( ) — 148KB
- grtx-20240321.xsd (EX-101.SCH) — 3KB
- grtx-20240321_lab.xml (EX-101.LAB) — 18KB
- grtx-20240321_pre.xml (EX-101.PRE) — 11KB
- d797057d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: March 27, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer